EyePoint (EYPT) Total Non-Current Liabilities (2011 - 2026)
EyePoint (EYPT) posted Total Non-Current Liabilities of $57.7 million for Q1 2026, little changed sequentially from $57.8 million in Q4 2025, and down 9.85% YoY from $64.0 million in Q1 2025.
Analysis
EyePoint (EYPT) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
EyePoint has reported Total Non-Current Liabilities for 11 years, with the latest figure at $57.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 9.85% year-over-year to $57.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 million (down 9.85% YoY) and the FY2025 annual result came in at $57.8 million, down 29.31% from the prior year.
- Total Non-Current Liabilities held at $57.7 million in Q1 2026 per EYPT's latest filing, from $57.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $118.4 million in Q2 2023 and troughed at $51.4 million in Q3 2025.
- A 5-year average of $78.5 million and a median of $81.5 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 45.33% in 2023, then tumbled 42.69% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $83.4 million in 2022, then increased by 6.56% to $88.9 million in 2023, then declined by 7.99% to $81.8 million in 2024, then slipped by 29.31% to $57.8 million in 2025, then fell by 0.18% to $57.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $57.7 million, $57.8 million, and $51.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 61.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.76 Mn |
| Mar 31, 2026 | 57.69 Mn |
| Dec 31, 2025 | 57.80 Mn |
| Sep 30, 2025 | 51.40 Mn |
| Jun 30, 2025 | 54.99 Mn |
| Mar 31, 2025 | 63.99 Mn |
| Dec 31, 2024 | 81.76 Mn |
| Sep 30, 2024 | 81.95 Mn |
| Jun 30, 2024 | 95.34 Mn |
| Mar 31, 2024 | 78.81 Mn |
| Dec 31, 2023 | 88.86 Mn |
| Sep 30, 2023 | 101.42 Mn |
| Jun 30, 2023 | 118.39 Mn |
| Mar 31, 2023 | 75.60 Mn |
| Dec 31, 2022 | 83.39 Mn |
| Sep 30, 2022 | 83.54 Mn |
| Jun 30, 2022 | 81.47 Mn |
| Mar 31, 2022 | 77.08 Mn |
| Dec 31, 2021 | 76.64 Mn |
| Sep 30, 2021 | 73.14 Mn |